{"nctId":"NCT04650087","briefTitle":"COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis","startDateStruct":{"date":"2021-02-15","type":"ACTUAL"},"conditions":["Covid19"],"count":1291,"armGroups":[{"label":"Apixaban","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Apixaban 2.5 MG"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Apixaban 2.5 MG","otherNames":["Eliquis"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* • Age ≥ 18 years\n\n  * PCR-positive COVID-19 infection\n  * Hospitalized for two or more days\n\nExclusion Criteria:\n\n* Pre-existing indication for anticoagulation (e.g., pulmonary embolism or deep vein thrombosis; atrial fibrillation; mechanical cardiac valve)\n* Contraindication to antithrombotic therapy (e.g., known bleeding within the last 30 days requiring emergency room presentation or hospitalization; major surgery within 14 days; ischemic stroke, intracranial bleed or neurosurgery within 3 months.\n* Platelet count \\< 50,000/mcL\n* Hemoglobin \\<8 gm/dL\n* Renal insufficiency (eGFR \\< 30 mL/min/1.73 m2)\n* Pregnancy\n* Prison inmate\n* Life expectancy less than 90 days\n* Unwilling or unable to provide informed consent/unwilling or unable to complete the study protocol\n* Dual antiplatelet therapy that cannot be discontinued\n* Concomitant need for strong inducers/inhibitors of p-gp or CYP3A4","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Composite Outcome of Symptomatic Deep Vein Thrombosis, Pulmonary Embolism, Other Venous Thromboembolism, Ischemic Stroke, Myocardial Infarction, Other Arterial Thromboembolism, and All-cause Mortality as Measured by Hospital Records.","description":"Composite endpoint (CE) of venous and arterial thrombotic complications-including new, symptomatic proximal, or distal DVT of the upper or lower extremities, PE, and new thrombosis of other veins (including cerebral sinus and splanchnic veins), ischemic stroke, myocardial infarction, other arterial thromboembolism (e.g., mesenteric or acute limb ischemia), and all-cause mortality by day 30.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.31","spread":null},{"groupId":"OG001","value":"2.13","spread":null}]}]}]},{"type":"SECONDARY","title":"The Composite Outcome of All-cause Mortality and the EuroQoL Group 5-Dimension (EQ5D) Index Score.","description":"Composite endpoint of mortality and EQ5D index at Day 30. All mortality events will be considered worse than any possible EQ5D response \\[QOL\\&M30\\]. Death was designated as a score of 0. Scores range from 0 (where 0 is the value of a health state equivalent to dead) to 1 (the value of full health), with higher scores indicating higher health utility.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":null},{"groupId":"OG001","value":"0.93","spread":null}]}]}]},{"type":"SECONDARY","title":"The Composite Outcome of All-cause Mortality and the EQ5D Index Score.","description":"Composite endpoint of mortality and EQ5D index at Day 90. All mortality events will be considered worse than any possible EQ5D response. Death was designated as a score of 0. Scores range from 0 (where 0 is the value of a health state equivalent to dead) to 1 (the value of full health), with higher scores indicating higher health utility.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.94","spread":null},{"groupId":"OG001","value":"0.94","spread":null}]}]}]},{"type":"SECONDARY","title":"The Composite Outcome of Symptomatic Deep Vein Thrombosis, Pulmonary Embolism, Other Venous Thromboembolism, Ischemic Stroke, Myocardial Infarction, Other Arterial Thromboembolism, and All-cause Mortality as Measured by Hospital Records.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.80","spread":null},{"groupId":"OG001","value":"2.46","spread":null}]}]}]},{"type":"SECONDARY","title":"The Composite Outcome of Symptomatic Deep Vein Thrombosis, Pulmonary Embolism, Other Venous Thromboembolism, Ischemic Stroke, Myocardial Infarction, Other Arterial Thromboembolism, and All-cause Mortality as Measured by Hospital Records.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.80","spread":null},{"groupId":"OG001","value":"3.11","spread":null}]}]}]},{"type":"SECONDARY","title":"New, Symptomatic VTE (Inclusive of DVT, PE, or Other Venous Thrombosis) for up to 30 Days After Randomization as Measured by Hospital Records.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":null},{"groupId":"OG001","value":"0.82","spread":null}]}]}]},{"type":"SECONDARY","title":"New, Symptomatic ATE (Inclusive of Ischemic Stroke, MI, or Peripheral Arterial Thromboembolism) for up to 30 Days After Randomization as Measured by Hospital Records.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.49","spread":null},{"groupId":"OG001","value":"0.16","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With All-cause Mortality","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.48","spread":null},{"groupId":"OG001","value":"1.31","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"The Incidence of All-cause Rehospitalization for up to 90 Days After Randomization","description":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"The Individual Domains of EQ5D and the EQ5D Visual Analog Scale for 30 and 90 Days After Randomization","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":71,"n":610},"commonTop":["WORSENING COVID-19 PNEUMONIA","FALL","WORSENING PNEUMONIA","CHEST PAIN","ELEVATED D-DIMER"]}}}